Omega Fund Management, LLC: 13F holdings
CIK 16373592026Q2
| Positions | 10 |
|---|
| Reported value | $185.7m |
|---|
| Filed | 2026-08-14 |
|---|
Change since last quarter
| Positions | 10 (+0 vs prior quarter) |
|---|
| Reported value | $185.7m (+13.8%) |
|---|
Top 10 holdings
| Security | Shares | Value | Weight |
|---|
| BCAX Bicara Therapeutics Inc. | 1,822,150 | $54.1m | 29.1% |
| NUVB Nuvation Bio Inc. | 8,081,089 | $45.9m | 24.7% |
| Kestra Med Technologies Ltd | 1,022,149 | $26.0m | 14.0% |
| BBOT BridgeBio Oncology Therapeutics Inc. | 3,289,661 | $25.1m | 13.5% |
| BBNX Beta Bionics Inc. | 1,316,183 | $20.6m | 11.1% |
| ALMS Alumis Inc. | 241,255 | $6.8m | 3.7% |
| SANA Sana Biotechnology, Inc. | 843,750 | $2.9m | 1.6% |
| ImageneBio, Inc. | 455,361 | $2.7m | 1.4% |
| enGene Holdings Inc. | 876,357 | $1.5m | 0.8% |
| Odyssey Therapeutics Inc. | 2,893 | $54,128 | 0.0% |
Get the full book
import finzdata as yf
yf.Client().manager_holdings(cik="1637359")
Every position, quarter by quarter since 2013, with adds, trims and exits, on the look-back bundles.
Get a free API keySee history bundlesDownload free samples